Abstract
-
▲ Sorafenib is an orally active multikinase inhibitor with anti-tumour activity. It was recently approved in the US and the EU for the treatment of patients with hepatocellular carcinoma.
-
▲ Oral sorafenib 400 mg twice daily significantly improved survival in patients with advanced hepatocellular carcinoma in the randomized, double-blind, multicentre, phase III SHARP trial (n = 602); the median duration of survival was 10.7 months with sorafenib and 7.9 months with placebo. In addition, the median time to progression was significantly longer in patients receiving sorafenib than in those receiving placebo (5.5 vs 2.8 months).
-
▲ Combination therapy with oral sorafenib 400 mg twice daily and intravenous doxorubicin has potential in the treatment of patients with advanced hepatocellular carcinoma, according to the results of a randomized, double-blind, phase II study (n = 96). Although the addition of sorafenib to doxorubicin did not significantly delay the time to progression, the median durations of overall survival and progression-free survival were significantly longer with sorafenib plus doxorubicin than with doxorubicin alone.
-
▲ Monotherapy with oral sorafenib 400 mg twice daily was generally well tolerated in patients with advanced hepatocellular carcinoma, with a manageable adverse event profile.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Roberts LR, Gores GJ. Emerging drugs for hepatocellular carcinoma. Expert Opin Emerg Drugs 2006; 11(3): 469–87
Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/ 5. Cancer Res 2006 Dec 15; 66(24): 11851–8
Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006 Oct; 5(10): 835–44
Adnane L, Trail PA, Taylor I, et al. Sorafenib (BAY 43-9006, Nexavar®), a dual-action inhibitor that targets RAF/MEK/ ERK pathway in tumor cells and tyrosine kinases VEGFR/ PDGFR in tumor vasculature. Methods Enzymol 2005; 407: 597–612
McKeage K, Wagstaff AJ. Sorafenib in advanced renal cancer. Drugs 2007; 67(3): 475–83
Bayer Pharmaceuticals Corporation. Nexavar® becomes first and only approved treatment of hepatocellular carcinoma in Europe [media release]. Available from URL: http://www.press.bayer.com [Accessed 2007 Nov 22]
Bayer Pharmaceuticals Corporation. Nexavar® first FDA-approved drug therapy for liver cancer [media release]. Available from URL: http://www.press.bayer.com[Accessed 2007 Nov 21]
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology™: hepatobiliary cancers. V.2.2008 [online]. Available from URL: http://www.nccn.org[Accessed 2007 Nov 22]
Wilhelm SM, Carter C, Tang LY, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004 Oct 1; 64(19): 7099–109
Lierman E, Folens C, Stover EH. Sorafenib is a potent inhibitor of FIPlLl-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant. Blood 2006 Aug 15; 108(4): 1374–6
Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006 Sep 10; 24(26): 4293–300
Lathia C, Lettieri J, Cihon F, et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006 May 1; 57(5): 685–92
Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92(10): 1855–61
Richly H, Henning BF, Kupsch P, et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006 May; 17(5): 866–73
Bayer Pharmaceuticals Corporation. Nexavar® (sorafenib) tablets, oral: prescribing information [online]. Available from URL: http://www.press.bayer.com[Accessed 2007 Nov 21]
Llovet J, Ricci S, Mazzaferro V, et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC) [abstract no. LBA1 plus oral presentation]. American Society of Clinical Oncology 43rd Annual Meeting; 2007 Jun 1–5; Chicago (IL)
Abou-Alfa G, Johnson P, Knox J, et al. Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC) [abstract plus slide presentation]. 14th European Cancer Conference; 2007 Sep 23–27; Barcelona
European Medicines Agency. Sorafenib (Nexavar): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Nov 21]
Acknowledgements and Disclosures
The manuscript was reviewed by: V. Mazzaferro, Gastrointestinal Surgery and Liver Transplantation Unit, National Cancer Institute, Milan, Italy; J.L. Raoul, Department of Medical Oncology, Centre E Marquis, Rennes, France; S. Zeuzem, Department of Medicine I, J.W. Goethe University Hospital, Frankfurt, Germany.
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Simpson, D., Keating, G.M. Sorafenib. Drugs 68, 251–258 (2008). https://doi.org/10.2165/00003495-200868020-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200868020-00007